|
Jul 01, 2022
|
BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat)
|
|
|
Jun 22, 2022
|
BioCryst Announces ORLADEYO® (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022
|
|
|
Jun 09, 2022
|
BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO® (berotralstat) in Latin America
|
|
|
Jun 08, 2022
|
FDA Grants Fast Track Designation for BioCryst’s ALK-2 Inhibitor, BCX9250
|
|
|
Jun 07, 2022
|
BioCryst Announces Approval of ORLADEYO® (berotralstat) by Swissmedic
|
|
|
Jun 06, 2022
|
BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks
|
|
|
Jun 01, 2022
|
BioCryst to Present at Upcoming Investor Conferences
|
|
|
May 06, 2022
|
BioCryst to Present at Upcoming Investor Conferences
|
|
|
May 05, 2022
|
BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones
|
|
|
May 04, 2022
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
